We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical's U.S. generic pipeline currently
consists of 140 product applications, 26 of which it hopes to gain marketing
exclusivity for, the company said in its fourth-quarter earnings report.
A pair of prominent House Democrats has introduced legislation that would prevent
government officials from tampering with federal research and scientific policymaking.
Illumina has signed a definitive agreement and plan of merger with CyVera, a
privately held Connecticut-based company, pursuant to which CyVera will become
a wholly owned subsidiary of Illumina.
Symyx Technologies has signed a definitive agreement to acquire privately-held
Synthematix, based in Research Triangle Park, N.C. Synthematix is a provider
of organic synthesis reaction planning software systems for scientific knowledge
management in chemistry research, with customers primarily in the pharmaceutical
and biotechnology industries.
Sentigen Holding has sold the Specialty Media Division of its wholly owned subsidiary,
Cell & Molecular Technologies to Chemicon International, a wholly owned
subsidiary of Serologicals Corporation.
Medco Health Solutions, the largest U.S. pharmacy-benefit manager, agreed to
buy Accredo Health for about $2.2 billion to expand its administration of drugs
for hard-to-treat diseases such as hemophilia.
Billionaire investor Carl Icahn has filed a lawsuit against generic drugmaker
Mylan Laboratories and its directors in a Pennsylvania court, challenging Mylan's
recent bylaw amendments that require any director nominations be completed within
the next week.
Biopharmaceutical company Insmed has filed a motion to dismiss a lawsuit filed
by Tercica and Genentech over efforts to commercialize its growth hormone SomatoKine
in the U.S. The company said its activities concerning SomatoKine fall under
federal clinical trial exemptions that prevent patent infringements from being
filed against a product that is being tested in clinical trials.
Nautilus Biotech has reached the first milestone
in its collaboration with Serono to develop a next-generation human growth hormone
with an improved pharmacological profile.